At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 906 enrolled
Drug / intervention
Ipilimumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
In Brief
A Phase 3 clinical trial evaluating Ipilimumab, Nivolumab, and 2 other interventions for Melanoma. Completed, enrolled 906 participants across 136 sites in 25 countries.
Detailed Summary
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesArgentina, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Greece, Hungary, Ireland, Italy, Japan, Netherlands, Norway, Poland, Romania, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMar 2015
Primary CompletionNov 2018
Study CompletionOct 2024
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartMar 16, 2015
Primary CompletionNov 26, 2018
Study CompletionOct 16, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.3 years ago
Interventions
Ipilimumabdrug
Specified dose on specified days
Nivolumabdrug
Specified dose on specified days
Placebo matching Ipilimumabother
Specified dose on specified days
Placebo matching Nivolumabother
Specified dose on specified days